Results 161 to 170 of about 9,896 (218)

Near-infrared photochemical internalization: design of a distorted zinc phthalocyanine for efficient intracellular delivery of immunotoxins. [PDF]

RSC Med Chem
Hamabe M, Dewa W, Yuki M, Yamada E, Aiba T, Horikoshi K, Hamakubo T, Ohashi R, Okamoto A.   +8 more
europepmc   +1 more source

Nuclear Imaging Strategies to Evaluate Cytokine Production in Autoimmune, Inflammatory, and Neoplastic Diseases: A Review of Current Preclinical Research. [PDF]

J Nucl Med
Deck A, Lane S, Liles A, Viola NT.
europepmc   +1 more source

Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation. [PDF]

Cancer Biol Ther
Wu Z, Fu X, Feng Y, Zeng R, Qin H, Yao K.   +5 more
europepmc   +1 more source

Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. [PDF]

J Clin Invest
Aminov S, Giricz O, Melnekoff DT, Sica RA, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN, Parekh S, Verma A.   +26 more
europepmc   +1 more source

Intracellular trafficking of furin enhances cellular intoxication by recombinant immunotoxins based on Pseudomonas exotoxin A. [PDF]

Biol Open
Grossman BD, Sanford JD, Zhu Y, Zeller CB, Weldon JE.   +4 more
europepmc   +1 more source

Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs. [PDF]

Eur J Pharmacol
Wang Z, Ramakrishna R, Wang Y, Qiu Y, Ma J, Mintzlaff D, Zhang H, Li B, Hammell B, Lucia MS, Pomfret E, Su AA, Washington KM, Mathes DW, Wang Z.   +14 more
europepmc   +1 more source

Recent Advances in Management of Vitiligo.

Indian J Dermatol
Das K, Sarkar R, Sinha S.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunotoxins and nanobody-based immunotoxins: review and update

Journal of Drug Targeting, 2021
Immunotoxins (ITs) are protein-based drugs that compose of targeting and cytotoxic moieties. After binding the IT to the specific cell-surface antigen, the IT internalises into the target cell and kills it. Targeting and cytotoxic moieties usually include monoclonal antibodies and protein toxins with bacterial or plant origin, respectively.
Mohammad Reza Khirehgesh, Jafar Sharifi, Fatemeh Safari, Bahman Akbari   +3 more
openaire   +2 more sources

Immunotoxins: An Update

Annual Review of Immunology, 1996
The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell ...
G R, Thrush, L R, Lark, B C, Clinchy, E S, Vitetta   +3 more
openaire   +2 more sources

Neurotoxicity of immunotoxins

Molecular and chemical neuropathology, 1994
Immunotoxins are being tested for the therapy of systemic cancer and brain tumors. Neurotoxicity has been dose limiting for several of these antibody conjugates given systemically. We review the animal and clinical data related to the neurotoxicity of immunotoxins in attempt to understand the molecular basis for the unexpected neural involvement and to
O, Ilercil, D W, Laske, S, Walbridge, K, Muaszko, E H, Oldfield, R J, Youle   +5 more
openaire   +2 more sources